Beyond Shielding: The Roles of Glycans in SARS-CoV-2 Spike Protein

The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in more than 15,000,000 infections and 600,000 deaths worldwide to date. Antibody development efforts mainly revolve around the extensively glycosylated SARS-CoV-2 spike (S) protein, which mediates the host cell entry by binding to the angiotensin-converting enzyme 2 (ACE2). Similar to many other viruses, the SARS-CoV-2 spike utilizes a glycan shield to thwart the host immune response. Here, we built a full-length model of glycosylated SARS-CoV-2 S protein, both in the open and closed states, augmenting the available structural and biological data. Multiple microsecond-long, all-atom molecular dynamics simulations were used to provide an atomistic perspective on the roles of glycans, and the protein structure and dynamics. We reveal an essential structural role of N-glycans at sites N165 and N234 in modulating the conformational dynamics of the spike’s receptor binding domain (RBD), which is responsible for ACE2 recognition. This finding is corroborated by biolayer interferometry experiments, which show that deletion of these glycans through N165A and N234A mutations significantly reduces binding to ACE2 as a result of the RBD conformational shift towards the “down” state. Additionally, end-to-end accessibility analyses outline a complete overview of the vulnerabilities of the glycan shield of SARS-CoV-2 S protein, which may be exploited by therapeutic efforts targeting this molecular machine. Overall, this work presents hitherto unseen functional and structural insights into the SARS-CoV-2 S protein and its glycan coat, providing a strategy to control the conformational plasticity of the RBD that could be harnessed for vaccine development.

[1]  John E. Schiel,et al.  Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells , 2019, Journal of Virology.

[2]  Alexander D. MacKerell,et al.  CHARMM Additive All-Atom Force Field for Glycosidic Linkages between Hexopyranoses. , 2009, Journal of chemical theory and computation.

[3]  V. Sasisekharan,et al.  Glycan–protein interactions in viral pathogenesis , 2016, Current Opinion in Structural Biology.

[4]  R. Owens,et al.  Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike , 2020, Cell Host & Microbe.

[5]  A. Pollard,et al.  Limb proportions show developmental plasticity in response to embryo movement , 2017, Scientific Reports.

[6]  Alexander D. MacKerell,et al.  Glycan reader: Automated sugar identification and simulation preparation for carbohydrates and glycoproteins , 2011, J. Comput. Chem..

[7]  Frank Grosveld,et al.  A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.

[8]  Ilya J. Finkelstein,et al.  Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes , 2020, bioRxiv.

[9]  Zachary T. Berndsen,et al.  Vulnerabilities in coronavirus glycan shields despite extensive glycosylation , 2020, Nature Communications.

[10]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[11]  D. Higgins,et al.  Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega , 2011, Molecular systems biology.

[12]  D. Matthews,et al.  Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein , 2020, Genome Medicine.

[13]  M. Crispin,et al.  Structural principles controlling HIV envelope glycosylation. , 2017, Current opinion in structural biology.

[14]  Robert J. Woods,et al.  3D Models of glycosylated SARS-CoV-2 spike protein suggest challenges and opportunities for vaccine development , 2020 .

[15]  M. Berkowitz,et al.  Detailed molecular dynamics simulations of model biological membranes containing cholesterol. , 2009, Biochimica et biophysica acta.

[16]  Alexandra C Walls,et al.  Structural basis for human coronavirus attachment to sialic acid receptors , 2019, Nature Structural & Molecular Biology.

[17]  I. Wilson,et al.  Exploitation of glycosylation in enveloped virus pathobiology , 2019, Biochimica et Biophysica Acta (BBA) - General Subjects.

[18]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[19]  M. Klein,et al.  Constant pressure molecular dynamics algorithms , 1994 .

[20]  C. Hillyer,et al.  Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses , 2020, Trends in Immunology.

[21]  Daniel Wrapp,et al.  Site-specific analysis of the SARS-CoV-2 glycan shield , 2020, bioRxiv.

[22]  Joanna Ellis,et al.  Characterisation of the transcriptome and proteome of SARS-CoV-2 using direct RNA sequencing and tandem mass spectrometry reveals evidence for a cell passage induced in-frame deletion in the spike glycoprotein that removes the furin-like cleavage site , 2020, bioRxiv.

[23]  E. Fadda,et al.  Sequence-to-structure dependence of isolated IgG Fc complex biantennary N-glycans: A molecular dynamics study , 2018, bioRxiv.

[24]  K. To,et al.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.

[25]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[26]  N. Callewaert,et al.  Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies , 2020, Cell.

[27]  Christian Cole,et al.  JPred4: a protein secondary structure prediction server , 2015, Nucleic Acids Res..

[28]  S. Roszak,et al.  NMR studies of daidzein and puerarin: active anti-oxidants in traditional Chinese medicine , 2019, Journal of Molecular Modeling.

[29]  Zhènglì Shí,et al.  Origin and evolution of pathogenic coronaviruses , 2018, Nature Reviews Microbiology.

[30]  G. Meer,et al.  Membrane lipids: where they are and how they behave , 2008, Nature Reviews Molecular Cell Biology.

[31]  Dennis R Burton,et al.  Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens , 2010, Proceedings of the National Academy of Sciences.

[32]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[33]  Karl Nicholas Kirschner,et al.  GLYCAM06: A generalizable biomolecular force field. Carbohydrates , 2008, J. Comput. Chem..

[34]  Rommie E. Amaro,et al.  Multiscale simulations examining glycan shield effects on drug binding to influenza neuraminidase , 2020, bioRxiv.

[35]  Mario Orsi,et al.  Physical properties of model biological lipid bilayers: insights from all-atom molecular dynamics simulations , 2019, Journal of Molecular Modeling.

[36]  Asif Shajahan,et al.  Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2 , 2020, bioRxiv.

[37]  D. Burton,et al.  The Glycan Shield of HIV Is Predominantly Oligomannose Independently of Production System or Viral Clade , 2011, PloS one.

[38]  David Hua,et al.  Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140 , 2015, Journal of Virology.

[39]  Robert J. Woods,et al.  Analysis of the SARS-CoV-2 spike protein glycan shield: implications for immune recognition , 2020, bioRxiv.

[40]  Xinquan Wang,et al.  Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2 , 2018, PLoS pathogens.

[41]  Lisa E. Gralinski,et al.  Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals , 2020, bioRxiv.

[42]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[43]  A. Steven,et al.  Engineering trimeric fibrous proteins based on bacteriophage T4 adhesins. , 1998, Protein engineering.

[44]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[45]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[46]  A. Helenius,et al.  Role of DC-SIGN in Lassa Virus Entry into Human Dendritic Cells , 2013, Journal of Virology.

[47]  M. Mckee,et al.  If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future , 2020, Nature Medicine.

[48]  Yang Zhang,et al.  I-TASSER: a unified platform for automated protein structure and function prediction , 2010, Nature Protocols.

[49]  S. Maurer-Stroh,et al.  Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[50]  A. Cunningham,et al.  DC-SIGN 'AIDS' HIV immune evasion and infection , 2007, Nature Immunology.

[51]  K. Nishiyama,et al.  Molecular dynamics study of binary POPC bilayers: molecular condensing effects on membrane structure and dynamics , 2018, Journal of Physics: Conference Series.

[52]  Yang Yang,et al.  A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 , 2020, Science.

[53]  R. Pastor,et al.  Permeability of membranes in the liquid ordered and liquid disordered phases , 2019, Nature Communications.

[54]  Sunhwan Jo,et al.  CHARMM‐GUI Membrane Builder toward realistic biological membrane simulations , 2014, J. Comput. Chem..

[55]  Nicholas C. Wu,et al.  A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.

[56]  Mario J. Borgnia,et al.  Controlling the SARS-CoV-2 spike glycoprotein conformation , 2020, Nature Structural & Molecular Biology.

[57]  H. Geuze,et al.  Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding , 1994, Journal of virology.

[58]  Sebastian Maurer-Stroh,et al.  Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2 , 2020, bioRxiv.

[59]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[60]  Sunhwan Jo,et al.  CHARMM-GUI Glycan Modeler for modeling and simulation of carbohydrates and glycoconjugates , 2019, Glycobiology.

[61]  B. Brooks,et al.  Constant pressure molecular dynamics simulation: The Langevin piston method , 1995 .

[62]  Amalio Telenti,et al.  Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.

[63]  Adrian J Mulholland,et al.  A Community Letter Regarding Sharing Biomolecular Simulation Data for COVID-19 , 2020, J. Chem. Inf. Model..

[64]  Haixia Zhou,et al.  Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding , 2016, Cell Research.

[65]  Young Do Kwon,et al.  Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G , 2016, Cell.

[66]  D. Beglov,et al.  Finite representation of an infinite bulk system: Solvent boundary potential for computer simulations , 1994 .

[67]  Rommie E. Amaro,et al.  Human Influenza A Virus Hemagglutinin Glycan Evolution Follows a Temporal Pattern to a Glycan Limit , 2019, mBio.

[68]  L. Gresh,et al.  Novel correlates of protection against pandemic H1N1 influenza A virus infection , 2019, Nature Medicine.

[69]  M. V. van Breemen,et al.  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.

[70]  C. Schiffer,et al.  A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction , 2020, Nature Communications.

[71]  Douglas S Kwon,et al.  DC-SIGN, a Dendritic Cell–Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells , 2000, Cell.

[72]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[73]  Yang Zhang,et al.  I-TASSER server for protein 3D structure prediction , 2008, BMC Bioinformatics.

[74]  Lai-Xi Wang,et al.  Conformational Heterogeneity of the HIV Envelope Glycan Shield , 2017, Scientific Reports.

[75]  I. Wilson,et al.  A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.

[76]  Ozlem Keskin,et al.  Membrane-associated Ras dimers are isoform-specific: K-Ras dimers differ from H-Ras dimers. , 2016, The Biochemical journal.

[77]  J. L. Nieva,et al.  The three lives of viral fusion peptides , 2014, Chemistry and Physics of Lipids.

[78]  Daniel Wrapp,et al.  Site-specific glycan analysis of the SARS-CoV-2 spike , 2020, Science.

[79]  Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies , 2020, Cell.

[80]  Asif Shajahan,et al.  Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2 , 2020, Glycobiology.

[81]  Taehoon Kim,et al.  CHARMM‐GUI: A web‐based graphical user interface for CHARMM , 2008, J. Comput. Chem..

[82]  Bonnie E. Shook-Sa,et al.  . CC-BY-NC-ND 4 . 0 International licenseIt is made available under a is the author / funder , who has granted medRxiv a license to display the preprint in perpetuity , 2021 .

[83]  R. Friesner,et al.  Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding Domains , 2020, bioRxiv.

[84]  Yang Zhang,et al.  Protein-ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment , 2013, Bioinform..

[85]  C. Schiffer,et al.  IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity , 2020, bioRxiv.

[86]  Derek N Woolfson,et al.  A coiled-coil motif that sequesters ions to the hydrophobic core , 2009, Proceedings of the National Academy of Sciences.

[87]  A. Gorfe,et al.  Simulating POPC and POPC/POPG Bilayers: Conserved Packing and Altered Surface Reactivity. , 2010, Journal of chemical theory and computation.

[88]  P. Rottier,et al.  Characterization of the budding compartment of mouse hepatitis virus: evidence that transport from the RER to the Golgi complex requires only one vesicular transport step , 1994, The Journal of cell biology.

[89]  Jan H. Jensen,et al.  PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.

[90]  Lu Lu,et al.  Identification of Human Single-Domain Antibodies against SARS-CoV-2 , 2020, Cell Host & Microbe.

[91]  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.

[92]  Jf. Nagle.  Mechanical properties of lipid bilayers , 2017 .

[93]  J. Boscarino,et al.  Palmitoylations on Murine Coronavirus Spike Proteins Are Essential for Virion Assembly and Infectivity , 2006, Journal of Virology.

[94]  R. Pastor,et al.  Mechanical properties of lipid bilayers from molecular dynamics simulation. , 2015, Chemistry and physics of lipids.

[95]  G. Whittaker,et al.  Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites , 2009, Proceedings of the National Academy of Sciences.

[96]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[97]  Ilya J. Finkelstein,et al.  Structure-based design of prefusion-stabilized SARS-CoV-2 spikes , 2020, Science.

[98]  Shibo Jiang,et al.  Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. , 2020, Antiviral research.

[99]  Ian A Wilson,et al.  Structure and Immune Recognition of the HIV Glycan Shield. , 2018, Annual review of biophysics.

[100]  T. Róg,et al.  Cholesterol effects on a mixed-chain phosphatidylcholine bilayer: a molecular dynamics simulation study. , 2006, Biochimie.

[101]  P. Sachs,et al.  SMARCAD1 ATPase activity is required to silence endogenous retroviruses in embryonic stem cells , 2019, Nature Communications.

[102]  Tongqing Zhou,et al.  A pH-dependent switch mediates conformational masking of SARS-CoV-2 spike , 2020, bioRxiv : the preprint server for biology.

[103]  P. Escribá,et al.  Membrane Lipid Composition: Effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues , 2019, International journal of molecular sciences.

[104]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[105]  D. Ermak,et al.  Brownian dynamics with hydrodynamic interactions , 1978 .

[106]  Jingqiu Cheng,et al.  Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins , 2020, bioRxiv.

[107]  Barney S. Graham,et al.  Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen , 2017, Proceedings of the National Academy of Sciences.

[108]  P. Carmeliet,et al.  PHD1 controls muscle mTORC1 in a hydroxylation-independent manner by stabilizing leucyl tRNA synthetase , 2020, Nature Communications.

[109]  Lisa E. Gralinski,et al.  Potently neutralizing and protective human antibodies against SARS-CoV-2 , 2020, Nature.

[110]  Qiang Zhou,et al.  A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 , 2020, Science.

[111]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[112]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[113]  Qiang Zhou,et al.  A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability , 2020, bioRxiv.

[114]  Jing Huang,et al.  CHARMM36 all‐atom additive protein force field: Validation based on comparison to NMR data , 2013, J. Comput. Chem..

[115]  V. Cheng,et al.  Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection , 2007, Clinical Microbiology Reviews.

[116]  T. Gallagher,et al.  Role of Spike Protein Endodomains in Regulating Coronavirus Entry* , 2009, The Journal of Biological Chemistry.

[117]  A. Shrake,et al.  Environment and exposure to solvent of protein atoms. Lysozyme and insulin. , 1973, Journal of molecular biology.

[118]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[119]  Thomas J Lane,et al.  MDTraj: a modern, open library for the analysis of molecular dynamics trajectories , 2014, bioRxiv.